JESSUP, Md., March 22 /PRNewswire/ -- ACell, Inc. announced that it has completed a $6.0 million financing. Capital raised in this first round of financing will be used for general corporate purposes, including strengthening ACell's position as the leader in regenerative medicine-based veterinary products and developing the Company's portfolio of medical products.
Jim DeFrancesco, ACell's CEO, stated: "We are pleased to have completed our first round of financing, and are encouraged by the tremendous interest shown in ACell and our proprietary technology. This financing will enable ACell to expand our base of veterinary customers while we move ACell's regenerative medicine-based products forward in the medical field."
ACell, Inc. was incorporated in Delaware in June 1999 for the purpose of developing, manufacturing, and marketing products in the field of regenerative medicine. These tissue engineered products are based on naturally occurring, extracellular matrix (ECM) scaffolds. The Company's proprietary ECM technology changes the fundamental healing response by encouraging the body's own regenerative capabilities to repair tissues and restore them to natural health. ACell currently markets veterinary products that promote the restoration of tissue in acute and chronic skin wounds, surgery, corneal ulcers, and tendon and ligament injuries.
CONTACT: Miles Grody of ACell, Inc., +1-301-983-6830, firstname.lastname@example.org